A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
Childhood cancer patients treated with platinums often develop hearing loss and the degree is classified according to different scales globally. Our objective was to compare concordance between five well-known ototoxicity scales used for childhood cancer patients. Audiometric test results (n = 654)...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0210646 |
| _version_ | 1831682236683911168 |
|---|---|
| author | E Clemens B Brooks A C H de Vries M van Grotel M M van den Heuvel-Eibrink B Carleton |
| author_facet | E Clemens B Brooks A C H de Vries M van Grotel M M van den Heuvel-Eibrink B Carleton |
| author_sort | E Clemens |
| collection | DOAJ |
| description | Childhood cancer patients treated with platinums often develop hearing loss and the degree is classified according to different scales globally. Our objective was to compare concordance between five well-known ototoxicity scales used for childhood cancer patients. Audiometric test results (n = 654) were evaluated longitudinally and graded according Brock, Chang, International Society of Pediatric Oncology (SIOP) Boston, Muenster scales and the U.S. National Cancer Institute Common Technology Criteria for Adverse Events (CTCAE) version 4.03. Adverse effects of grade 2, 3 and 4 are considered to reflect a degree of hearing loss sufficient to interfere with day-to-day communication (> = Chang grade 2a; > = Muenster grade 2b). We term this "deleterious hearing loss". A total number of 3,799 audiograms were evaluated. The prevalence of deleterious hearing loss according to the last available audiogram of each patient was 59.3% (388/654) according to Muenster, 48.2% (315/653) according to SIOP, 40.5% (265/652) according to Brock, 40.3% (263/652) according to Chang, and 57.5% (300/522) according to CTCAEv4.03. Overall concordance between the scales ranged from ĸ = 0.636 (Muenster vs. Chang) to ĸ = 0.975 (Brock vs. Chang). Muenster detected hearing loss the earliest in time, followed by Chang, SIOP and Brock. Generally good concordance between the scales was observed but there is still diversity in definitions of functional outcomes, such as differences in distribution levels of severity of hearing loss, and additional intermediate scales taking into account losses <40 dB as well. Regardless of the scale used, hearing function decreases over time and therefore, close monitoring of hearing function at baseline and with each cycle of platinum therapy should be conducted. |
| first_indexed | 2024-12-20T06:14:46Z |
| format | Article |
| id | doaj.art-23c096cb14d8485bb46c913e3db8b378 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T06:14:46Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-23c096cb14d8485bb46c913e3db8b3782022-12-21T19:50:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01142e021064610.1371/journal.pone.0210646A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.E ClemensB BrooksA C H de VriesM van GrotelM M van den Heuvel-EibrinkB CarletonChildhood cancer patients treated with platinums often develop hearing loss and the degree is classified according to different scales globally. Our objective was to compare concordance between five well-known ototoxicity scales used for childhood cancer patients. Audiometric test results (n = 654) were evaluated longitudinally and graded according Brock, Chang, International Society of Pediatric Oncology (SIOP) Boston, Muenster scales and the U.S. National Cancer Institute Common Technology Criteria for Adverse Events (CTCAE) version 4.03. Adverse effects of grade 2, 3 and 4 are considered to reflect a degree of hearing loss sufficient to interfere with day-to-day communication (> = Chang grade 2a; > = Muenster grade 2b). We term this "deleterious hearing loss". A total number of 3,799 audiograms were evaluated. The prevalence of deleterious hearing loss according to the last available audiogram of each patient was 59.3% (388/654) according to Muenster, 48.2% (315/653) according to SIOP, 40.5% (265/652) according to Brock, 40.3% (263/652) according to Chang, and 57.5% (300/522) according to CTCAEv4.03. Overall concordance between the scales ranged from ĸ = 0.636 (Muenster vs. Chang) to ĸ = 0.975 (Brock vs. Chang). Muenster detected hearing loss the earliest in time, followed by Chang, SIOP and Brock. Generally good concordance between the scales was observed but there is still diversity in definitions of functional outcomes, such as differences in distribution levels of severity of hearing loss, and additional intermediate scales taking into account losses <40 dB as well. Regardless of the scale used, hearing function decreases over time and therefore, close monitoring of hearing function at baseline and with each cycle of platinum therapy should be conducted.https://doi.org/10.1371/journal.pone.0210646 |
| spellingShingle | E Clemens B Brooks A C H de Vries M van Grotel M M van den Heuvel-Eibrink B Carleton A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. PLoS ONE |
| title | A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. |
| title_full | A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. |
| title_fullStr | A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. |
| title_full_unstemmed | A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. |
| title_short | A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. |
| title_sort | comparison of the muenster siop boston brock chang and ctcaev4 03 ototoxicity grading scales applied to 3 799 audiograms of childhood cancer patients treated with platinum based chemotherapy |
| url | https://doi.org/10.1371/journal.pone.0210646 |
| work_keys_str_mv | AT eclemens acomparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT bbrooks acomparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT achdevries acomparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT mvangrotel acomparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT mmvandenheuveleibrink acomparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT bcarleton acomparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT eclemens comparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT bbrooks comparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT achdevries comparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT mvangrotel comparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT mmvandenheuveleibrink comparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy AT bcarleton comparisonofthemuenstersiopbostonbrockchangandctcaev403ototoxicitygradingscalesappliedto3799audiogramsofchildhoodcancerpatientstreatedwithplatinumbasedchemotherapy |